Pliant Therapeutics Inc (NASDAQ:PLRX) currently has a daily average trading volume of 2.75M but it saw 843296 shares traded in last market. With a market cap of 97.60M USD, the company’s current market price of $1.59 came rising about 7.43 while comparing to the previous closing price of $1.48. In past 52 weeks, the stock remained buoying in the range of price level as high as $16.52 and as low as $1.10. In the recent trading on the day, stock has struck highest price mark of $1.43 while lowest mark touched by it was $1.6.
Taking a look at 20-day trading activity of Pliant Therapeutics Inc (PLRX) gives us an average price of $1.4155, while its current price level is -90.38% below from 52-week high level whereas it is 44.53% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.7379 while that of 200 days or SMA-200 reads an average of $9.8381. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.57% during that period while stretching the period over a month that increases to 8.48%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.06 which implies that the stock is in neutral territory.
Over the week, PLRX’s stock price is moving 3.25% up while it is 17.78% when we observe its performance for the past one month. Year-to-date it is -87.93% down and over the past year, the stock is showing a downside performance of -86.54%.
The company is expected to be releasing its next quarterly report on 2025-Mar-02, for which analysts forecasted an EPS of -0.75 while estimate for next year EPS is -2.29.
Currently, Pliant Therapeutics Inc’s total number of outstanding shares is 60.86M with 3.26% of that held by the insiders while 115.28% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -57.82% and return on equity (ROE) at -54.09%. Stock’s beta reads 1.45. Stock has a price to book (P/B) ratio of 0.32. Its return on asset (ROA) is -46.27% on average.
